vs
Enovis CORP（ENOV）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是Enovis CORP的1.7倍（$906.4M vs $548.9M），Rollins, Inc.净利率更高（11.9% vs -104.1%，领先115.9%），Rollins, Inc.同比增速更快（10.2% vs -2.2%），Rollins, Inc.自由现金流更多（$111.2M vs $29.1M），过去两年Enovis CORP的营收复合增速更高（9.8% vs 0.8%）
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
ENOV vs ROL — 直观对比
营收规模更大
ROL
是对方的1.7倍
$548.9M
营收增速更快
ROL
高出12.4%
-2.2%
净利率更高
ROL
高出115.9%
-104.1%
自由现金流更多
ROL
多$82.1M
$29.1M
两年增速更快
ENOV
近两年复合增速
0.8%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $548.9M | $906.4M |
| 净利润 | $-571.1M | $107.8M |
| 毛利率 | 59.9% | — |
| 营业利润率 | -101.7% | 16.1% |
| 净利率 | -104.1% | 11.9% |
| 营收同比 | -2.2% | 10.2% |
| 净利润同比 | 18.8% | 2.5% |
| 每股收益（稀释后） | $-9.99 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENOVROL
| Q1 26 | — | $906.4M | ||
| Q4 25 | $548.9M | $912.9M | ||
| Q3 25 | $564.5M | $1.0B | ||
| Q2 25 | $558.8M | $999.5M | ||
| Q1 25 | — | $822.5M | ||
| Q4 24 | $561.0M | $832.2M | ||
| Q3 24 | $505.2M | $916.3M | ||
| Q2 24 | $525.2M | $891.9M |
净利润ENOVROL
| Q1 26 | — | $107.8M | ||
| Q4 25 | $-571.1M | $116.4M | ||
| Q3 25 | $-36.7M | $163.5M | ||
| Q2 25 | $-56.0M | $141.5M | ||
| Q1 25 | — | $105.2M | ||
| Q4 24 | $-703.2M | $105.7M | ||
| Q3 24 | $-31.5M | $136.9M | ||
| Q2 24 | $-18.6M | $129.4M |
毛利率ENOVROL
| Q1 26 | — | — | ||
| Q4 25 | 59.9% | — | ||
| Q3 25 | 59.3% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 54.8% | — | ||
| Q3 24 | 56.7% | — | ||
| Q2 24 | 55.0% | — |
营业利润率ENOVROL
| Q1 26 | — | 16.1% | ||
| Q4 25 | -101.7% | 17.5% | ||
| Q3 25 | -3.0% | 21.9% | ||
| Q2 25 | -8.4% | 19.8% | ||
| Q1 25 | — | 17.3% | ||
| Q4 24 | -118.5% | 18.1% | ||
| Q3 24 | -6.3% | 20.9% | ||
| Q2 24 | -8.4% | 20.4% |
净利率ENOVROL
| Q1 26 | — | 11.9% | ||
| Q4 25 | -104.1% | 12.8% | ||
| Q3 25 | -6.5% | 15.9% | ||
| Q2 25 | -10.0% | 14.2% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | -125.4% | 12.7% | ||
| Q3 24 | -6.2% | 14.9% | ||
| Q2 24 | -3.5% | 14.5% |
每股收益（稀释后）ENOVROL
| Q1 26 | — | $0.22 | ||
| Q4 25 | $-9.99 | $0.24 | ||
| Q3 25 | $-0.64 | $0.34 | ||
| Q2 25 | $-0.98 | $0.29 | ||
| Q1 25 | — | $0.22 | ||
| Q4 24 | $-12.69 | $0.22 | ||
| Q3 24 | $-0.58 | $0.28 | ||
| Q2 24 | $-0.34 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.6M | $116.5M |
| 总债务越低越好 | $1.4B | $650.6M |
| 股东权益账面价值 | $2.0B | $1.4B |
| 总资产 | $4.4B | $3.2B |
| 负债/权益比越低杠杆越低 | 0.67× | 0.47× |
8季度趋势，按日历期对齐
现金及短期投资ENOVROL
| Q1 26 | — | $116.5M | ||
| Q4 25 | $33.6M | $100.0M | ||
| Q3 25 | $44.1M | $127.4M | ||
| Q2 25 | $38.5M | $123.0M | ||
| Q1 25 | — | $201.2M | ||
| Q4 24 | $48.2M | $89.6M | ||
| Q3 24 | $35.4M | $95.3M | ||
| Q2 24 | $35.0M | $106.7M |
总债务ENOVROL
| Q1 26 | — | $650.6M | ||
| Q4 25 | $1.4B | $486.1M | ||
| Q3 25 | $1.4B | $485.7M | ||
| Q2 25 | $1.4B | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | $1.3B | $395.3M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — |
股东权益ENOVROL
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $2.6B | $1.5B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | $2.6B | $1.3B | ||
| Q3 24 | $3.3B | $1.3B | ||
| Q2 24 | $3.3B | $1.2B |
总资产ENOVROL
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.4B | $3.1B | ||
| Q3 25 | $5.0B | $3.2B | ||
| Q2 25 | $4.9B | $3.2B | ||
| Q1 25 | — | $2.9B | ||
| Q4 24 | $4.7B | $2.8B | ||
| Q3 24 | $5.6B | $2.8B | ||
| Q2 24 | $5.4B | $2.8B |
负债/权益比ENOVROL
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.67× | 0.35× | ||
| Q3 25 | 0.54× | 0.32× | ||
| Q2 25 | 0.53× | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | 0.52× | 0.30× | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $82.6M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $111.2M |
| 自由现金流率自由现金流/营收 | 5.3% | 12.3% |
| 资本支出强度资本支出/营收 | 9.7% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.10× |
| 过去12个月自由现金流最近4个季度 | $22.8M | $621.1M |
8季度趋势，按日历期对齐
经营现金流ENOVROL
| Q1 26 | — | $118.4M | ||
| Q4 25 | $82.6M | $164.7M | ||
| Q3 25 | $47.8M | $191.3M | ||
| Q2 25 | $-1.6M | $175.1M | ||
| Q1 25 | — | $146.9M | ||
| Q4 24 | $88.3M | $188.2M | ||
| Q3 24 | $53.6M | $146.9M | ||
| Q2 24 | $7.8M | $145.1M |
自由现金流ENOVROL
| Q1 26 | — | $111.2M | ||
| Q4 25 | $29.1M | $159.0M | ||
| Q3 25 | $3.4M | $182.8M | ||
| Q2 25 | $-44.9M | $168.0M | ||
| Q1 25 | — | $140.1M | ||
| Q4 24 | $35.1M | $184.0M | ||
| Q3 24 | $2.4M | $139.4M | ||
| Q2 24 | $-31.6M | $136.4M |
自由现金流率ENOVROL
| Q1 26 | — | 12.3% | ||
| Q4 25 | 5.3% | 17.4% | ||
| Q3 25 | 0.6% | 17.8% | ||
| Q2 25 | -8.0% | 16.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | 6.3% | 22.1% | ||
| Q3 24 | 0.5% | 15.2% | ||
| Q2 24 | -6.0% | 15.3% |
资本支出强度ENOVROL
| Q1 26 | — | 0.8% | ||
| Q4 25 | 9.7% | 0.6% | ||
| Q3 25 | 7.9% | 0.8% | ||
| Q2 25 | 7.7% | 0.7% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | 9.5% | 0.5% | ||
| Q3 24 | 10.1% | 0.8% | ||
| Q2 24 | 7.5% | 1.0% |
现金转化率ENOVROL
| Q1 26 | — | 1.10× | ||
| Q4 25 | — | 1.41× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
ROL
暂无分部数据
